Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0001600620-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | 2026-01-02 | AUPH | Donley Matthew Maxwell | COO | F - Tax | $15.95 | -42.8K | 695.8K | -6% | -$682.5K | |
| 2026-01-05 | 2026-01-02 | AUPH | Donley Matthew Maxwell | COO | A - Grant | $0.00 | +54.2K | 734.6K | +8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | F | D | 42,787 | $15.95 | 695,801 | D | — | — | (F2) Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards. (F3) Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 30, 2025 and 1,457 common shares were acquired on November 28, 2025. |
| 2 | Common | Common Stock | 2026-01-02 | A | A | 54,166 | $0.00 | 734,631 | D | — | — | (F1) Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026. |